Core Insights - Despite a cautious market sentiment in November, public fund research enthusiasm remains strong, with 154 public funds participating in 4,298 research instances covering 506 stocks across 30 industries [1][2] - The stocks under research showed significant resilience, outperforming the CSI 300 index by 1.89 percentage points, with 186 stocks achieving positive returns, and 66 stocks rising over 10% [1][2] - Leading the gains was Huasheng Lithium with a monthly increase of 132.48%, while the electric equipment sector performed strongly, with Hai Lu Heavy Industry and Fengyuan Co. also making the top gainers list [1][4] Industry Focus - The electronic industry led the research activities with 974 instances covering 88 stocks, with Luxshare Precision, Industrial Fulian, and Aobi Zhongguang being the most researched [2][3] - The mechanical equipment sector followed closely with 819 research instances covering 71 stocks, focusing on companies like Huichuan Technology and Bo Ying Special Welding [2][3] - The pharmaceutical and biological sector ranked third with 403 research instances covering 38 stocks, highlighting companies like BeiGene and Ruimai Technology [2][3] Research Frequency and Performance - The top researched stocks included Luxshare Precision (142 instances), Huichuan Technology (81 instances), and Bo Ying Special Welding (71 instances) [4][7] - Notably, the stocks with the highest price increases also included multiple companies from the electronic and electric equipment sectors, indicating a correlation between research frequency and stock performance [5][6] - The research data reflects a trend where public funds are increasingly focusing on companies with potential technological breakthroughs and favorable market conditions [8][9] Institutional Activity - A total of 85 public funds conducted at least 20 research instances, with 25 funds exceeding 50 instances, indicating strong interest from leading institutions [6][7] - The top three funds by research frequency were Bosera Fund (111 instances), Huaxia Fund (101 instances), and Guotai Fund (93 instances) [6][7] - The research paths of these leading institutions showed a high degree of overlap, particularly focusing on Luxshare Precision, Huichuan Technology, and Bo Ying Special Welding [7][8] Trends and Insights - The research data reveals two key trends: a strong interest from top public funds in the electronic and mechanical equipment sectors, and an increasing resonance between research activities and market performance [9] - The focus of research is shifting towards more detailed and refined insights, emphasizing industry dynamics and technological innovations [9]

个股方面，12月2日，有1844只个股获融资净买入，净买入金额在3000万元以上的有139股。其中，22股 获融资净买入额超1亿元。新易盛获融资净买入额居首，净买入5.88亿元；融资净买入金额居前的还有 领益智造、生益电子、胜宏科技、宁德时代、贵州茅台、招商轮船、航天发展、佰维存储等股。 Wind统计显示，12月2日，申万31个一级行业中有16个行业获融资净买入，其中，汽车行业获融资净买 入额居首，当日净买入9.53亿元；获融资净买入居前的行业还有通信、国防军工、计算机、机械设备、 医药生物等。 ...

中邮证券指出，医药生物行业短暂回调后性价比凸显，随着集采、院内反腐等负面因素出清，2026 年有望表现突出。创新药方面，国内资产全球认可度快速提升，MNC专利悬崖迫近，新品迭代需求强 烈，美国药价政策频出，利好国产新药出海；医保商保协同发力，国产新药商业化前景优异。医疗器械 行业部分企业2025年三季度业绩迎来拐点，成长型企业整体增长稳定；设备板块招投标持续恢复，有望 兑现至2026年业绩；耗材集采逐渐进入尾声、IVD板块在集采冲击下行业整合提速，负面影响即将出 清，看好板块后续增长。 每日经济新闻 （责任编辑：董萍萍 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅达20%，该指数从创 业板市场中选取涉及生物医药、医疗器械及相关服务业务的上市公司证券作为指数样本，以反映创业板 医药健康产业相关上市公司证券的整体表现。创 ...

同花顺（300033）数据显示，截至12月2日，年内A股上市公司披露4290单并购项目，为去年同期的1.78 倍。 深圳市前海排排网基金销售有限责任公司研究员隋东告诉《证券日报》记者，并购市场活跃是政策、产 业与资本三重因素共同作用的结果。政策层面，多部委及地方积极鼓励围绕主业与新兴产业的并购，通 过简化程序、降低融资门槛及推动央企优质资源注入，为并购创造了有利环境。企业层面，无论是传统 企业突破增长瓶颈，还是科技企业补强研发短板，均将并购作为整合产业链、获取新技术、布局新赛道 以培育新增长点的关键手段。资本层面，各地产业并购基金的设立，以及现金收购、发行股份等灵活的 交易方式为并购提供了坚实的资金支持与资本结构优化方案，共同助推企业实现外延式增长。 并购火热的背后，一些新的特征已经显现。"活跃度显著提升；产业链纵向整合成为主流，企业更多地 通过并购补齐技术短板、贯通供应链或拓展新市场；市场对'硬科技'领域未盈利资产的包容度提升，支 付工具与业绩承诺也更趋灵活。"珠海黑崎资本投资管理合伙企业(有限合伙)首席战略官陈兴文告诉 《证券日报》记者，2025年并购市场呈现出诸多新变化。 在陈兴文看来，今年的并购市场出 ...

Core Viewpoint - The automotive and parts sector in A-shares has seen significant net buying in financing, ranking among the top five, while sectors such as steel II, pharmaceuticals, telecommunications services, medical devices, and non-bank financials have ranked among the bottom five in net buying [24]. Market Overview - As of November 28, 2025, the financing net buying amounts for various sectors have shown a clear disparity, with 23 out of 35 Wind secondary industry sectors experiencing net buying [24][25]. - The major indices in A-shares have all risen, with the Wind All A Index increasing by 2.90%, the Shanghai Composite Index by 1.40%, the Shenzhen Component Index by 3.56%, the ChiNext Index by 4.54%, the North 50 Index by 0.75%, and the Sci-Tech 50 Index by 3.21% [23]. Financing Net Buying Rankings - The top five sectors for net buying in the past week include: - Industrial Trade and Comprehensive: 94.90 billion - Semiconductor: 33.84 billion - Automotive and Parts: 7.81 billion - Hardware Equipment: 6.82 billion - Transportation: 6.57 billion [31] - The bottom five sectors for net buying in the past week include: - Medical Devices and Services: -1.31 billion - Steel II: -1.99 billion - Pharmaceuticals: -3.89 billion - Telecommunications Services: -4.90 billion - Non-Bank Financials: -24.50 billion [32]. Financing Balance Rankings - The top five sectors by financing balance are: - Hardware Equipment: 3,446.36 billion - Non-Bank Financials: 1,827.97 billion - Semiconductors: 1,800.99 billion - Electrical Equipment: 1,791.24 billion - Software Services: 1,500.74 billion [33].

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4433.77 points, down 0.69%, with a trading volume of 6.716 billion HKD and a turnover rate of 0.73% [1] - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at 3.66% and Health Road leading the decliners at 6.35% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (14.56% weight, latest price 200.62, market cap 243.24 billion) [1] - Yier Eye Hospital (11.62% weight, latest price 11.50, market cap 107.24 billion) [1] - Lejin Medical (4.85% weight, latest price 15.74, market cap 29.01 billion) [1] - Aimeike (4.80% weight, latest price 145.06, market cap 43.89 billion) [1] - Yuyue Medical (4.66% weight, latest price 35.82, market cap 35.91 billion) [1] - Yingke Medical (3.64% weight, latest price 42.40, market cap 27.78 billion) [1] - Furuide (3.59% weight, latest price 67.36, market cap 17.85 billion) [1] - Meinian Health (3.58% weight, latest price 5.21, market cap 20.39 billion) [1] - Sinopharm (3.35% weight, latest price 18.63, market cap 58.14 billion) [1] - Ping An Good Doctor (2.63% weight, latest price 13.39, market cap 28.93 billion) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 83.77 million HKD, while retail investors saw a net inflow of 61.08 million HKD [1] - Specific stock capital flows include: - Mindray Medical: main fund net inflow of 37.11 million, retail net outflow of 4.23 million [2] - Yuyue Medical: main fund net inflow of 3.70 million, retail net inflow of 4.71 million [2] - Over the past 10 days, one stock was newly added to the index [2]

Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) closed at 4523.97 points, down 0.72%, with a trading volume of 6.097 billion yuan and a turnover rate of 0.73% on December 2 [1]. Group 1: Index Performance - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at a 3.66% increase and Health Road leading the decliners at a 6.35% decrease [1]. - The top ten constituents of the Shenzhen-Hong Kong Medical Index include major companies such as Mindray Medical (14.56% weight, latest price 200.62 yuan, -0.50% change) and Aier Eye Hospital (11.62% weight, latest price 11.50 yuan, -0.60% change) [1]. Group 2: Capital Flow - The net outflow of main funds from the index constituents totaled 83.77 million yuan, while retail investors saw a net inflow of 61.08 million yuan [3]. - Specific stock capital flows indicate that Mindray Medical experienced a net inflow of 37.11 million yuan from main funds, while it faced a net outflow of 32.88 million yuan from speculative funds [3]. - The index constituents underwent an adjustment in the last 10 days, with one new stock added [3].

| 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 200.62 | -0.50% | 2432.40 | > 医药生物 | | sz000661 | 长春高新 | 4.87% | 98.98 | -1.11% | 403.78 | 医药生物 | | sz002252 | 十字典上 | 4.74% | 6.61 | -0.60% | 438.77 | 医药生物 | | sz300759 | 康龙化成 | 4.55% | 29.00 | -2.23% | 515.68 | 医药生物 | | sz300347 | 表格失药 | 4.54% | 48.80 | -3.88% | 420.18 | 医药生物 | | sz000021 | 深科技 | 4.16% | 23.98 | -2.56% | 376.89 | 电子 | | sz002714 | 牧原股份 | 3.62% | 49.13 | -1.15% | 2683.8 ...

Core Viewpoint - The article discusses the impact of AI on investment opportunities in the equity market, highlighting the volatility and potential for profit in specific sectors, particularly in Fujian's food industry and the commercial space sector [1][10]. Summary by Sections A-share Market Review - The A-share market experienced fluctuations, with the Shanghai Composite Index down by 0.42%, Shenzhen Component down by 0.68%, and the ChiNext Index down by 0.69% on December 2 [10]. - The total trading volume across the three markets was 16,073.75 billion, a decrease of 2,821.68 million from the previous day [10]. - Over 3,700 stocks declined, while 55 stocks hit the daily limit up, indicating a strong performance in certain sectors, particularly in Fujian [10]. Fujian Sector Insights - Fujian's food sector saw a significant surge following the announcement of 12 policies supporting Taiwanese residents to open Sha County snack stores, leading to a rapid increase in stock prices [1][3]. - Key companies in this sector include: - Hai Xin Food (002702): A century-old brand focusing on frozen foods, with a flagship store in Beijing [3]. - Hui Fa Food (603536): Specializes in frozen prepared dishes suitable for Sha County snacks [3]. - Other notable companies include Fu Ling Pickled Vegetables (002507), Gai Shi Food (920826), and An Ji Food (603696), all of which are positioned to benefit from the Sha County snack concept [3]. Commercial Space Sector - The commercial space sector is gaining momentum, with the Zhuque rocket scheduled for launch on December 3, which is expected to boost related stocks [10]. - The establishment of a dedicated Commercial Space Administration by the National Space Administration marks a significant step towards the development of China's commercial space industry [10]. AI Mobile Phone Concept - The AI mobile phone sector has shown volatility, with a recent surge followed by a decline, raising concerns about its sustainability [2]. - Morgan Stanley noted that the deployment of AI assistants in mobile phones requires deep technical collaboration with manufacturers, which may reshape the value distribution in the mobile market [2]. Market Trends and Predictions - The report from Morgan Stanley anticipates a modest profit growth of around 6-7% for 2026, lower than the market consensus of 15%, indicating potential adjustments in traditional sectors like consumer goods and real estate [6]. - The article emphasizes the need for continued support in the real estate market, with expectations for policy measures to stabilize housing prices and stimulate demand [8]. Investment Opportunities - The article highlights the potential for investment in sectors such as food and commercial space, driven by government policies and market dynamics [1][10]. - The focus on AI technology and its integration into various industries presents new avenues for growth and investment [2].

证券之星消息，12月2日，医疗健康R（480016）指数报收于7315.52点，跌1.46%，成交161.03亿元，换 手率0.53%。当日该指数成份股中，上涨的有4家，济川药业以1.0%的涨幅领涨，下跌的有46家，泰格医 药以3.88%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.66% | 89.42 | -3.12% | 2668.08 | 医药生物 | | sh600276 | 恒瑞医药 | 11.00% | 61.12 | -1.32% | 4056.66 | 医药生物 | | sz300760 | 迈瑞医疗 | 7.57% | 200.62 | -0.50% | 2432.40 | 医药生物 | | sh688271 | 联影医疗 | 4.27% | 128.71 | -1.97% | 1060.77 | 医药生物 | | sh600436 | 片 ...